Teva Pharmaceutical Industries Ltd. announced the successful completion of the enrollment in the EU and US of the anticipated 640 participants of the ongoing Phase 3 clinical trial of mdc-TJK (TEV-44749) at the J.P. Morgan Healthcare Conference. Results of the study are expected in the second half of 2024. mdc-TJK is an investigational once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine for the treatment of schizophrenia.

It has the potential to be the first long-acting olanzapine with a favorable safety profile. Teva remains fully responsible to lead the development and commercialization of olanzapine LAI globally. MedinCell may receive up to $117 million in development and commercial milestones over the coming years for mdc-TJK, and is eligible for royalties on all net sales.